Development of a Suicide Inhibition-Based Protein Labeling Strategy for Nicotinamide N-Methyltransferase by Sen, Sudeshna et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
University of Massachusetts Medical School Publications 
2019-04-19 
Development of a Suicide Inhibition-Based Protein Labeling 
Strategy for Nicotinamide N-Methyltransferase 
Sudeshna Sen 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/publications 
 Part of the Amino Acids, Peptides, and Proteins Commons, Biochemistry Commons, Cancer Biology 
Commons, Enzymes and Coenzymes Commons, Medicinal and Pharmaceutical Chemistry Commons, 
and the Medicinal-Pharmaceutical Chemistry Commons 
Repository Citation 
Sen S, Mondal S, Zheng L, Salinger AJ, Fast W, Weerapana E, Thompson PR. (2019). Development of a 
Suicide Inhibition-Based Protein Labeling Strategy for Nicotinamide N-Methyltransferase. University of 
Massachusetts Medical School Publications. https://doi.org/10.1021/acschembio.9b00211. Retrieved 
from https://escholarship.umassmed.edu/publications/15 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in University of 
Massachusetts Medical School Publications by an authorized administrator of eScholarship@UMMS. For more 
information, please contact Lisa.Palmer@umassmed.edu. 
Development of a Suicide Inhibition Based Protein Labeling (SIBLing) 
Strategy for Nicotinamide N-methyltransferase 
Sudeshna Sen†‡, Santanu Mondal†‡, Li Zheng†‡, Ari J. Salinger†‡, Walter Fast⸸, Eranthie 
Weerapana§ and Paul R. Thompson*†‡ 
 
 
 
†Department of Biochemistry and Molecular Pharmacology, University of Massachusetts 
Medical School, 364 Plantation Street, Worcester, Massachusetts 01605, United States. 
‡ Program in Chemical Biology, University of Massachusetts Medical School, 364 Plantation 
Street, Worcester, Massachusetts 01605, United States. 
⸸ Division of Chemical Biology and Medicinal Chemistry, College of Pharmacy, University of 
Texas, Austin, Texas 78712, United States. 
§ Department of Chemistry, Boston College, Chestnut Hill, Massachusetts 02467, United States. 
 
 
 
*Author to whom correspondence should be addressed: Department of Biochemistry and 
Molecular Pharmacology, University of Massachusetts Medical School, LRB 826, 364 
Plantation Street, 
Worcester, MA 01605 tel: 508-856-8492; fax: 508-856-6215; e-mail: 
paul.thompson@umassmed.edu. 
  
ABSTRACT 
Nicotinamide N-methytransferase (NNMT) catalyzes the S-adenosyl-L-methionine (SAM)-
dependent methylation of nicotinamide (NAM) to form N-methylnicotinamide (Me-NAM).  This 
enzyme detoxifies xenobiotics and regulates NAD+ biosynthesis.  Additionally, NNMT is 
overexpressed in various cancers.  Herein, we describe the first NNMT-targeted suicide 
substrates.  These compounds, which include 4-chloropyridine and 4-chloronicotinamide, exploit 
the broad substrate scope of NNMT; methylation of the pyridine nitrogen enhances the 
electrophilicity of the C4 position, thereby promoting an aromatic nucleophilic substitution by 
C159, a non-catalytic cysteine.  Based on this activity, we developed a suicide inhibition-based 
protein labeling (SIBLing) strategy using an alkyne-substituted 4-chloropyridine that selectively 
labels NNMT in vitro and in cells.  In total, this study describes the first NNMT-directed 
activity-based probes. 
   
 
 
 
  
Nicotinamide N-methyltransferase (NNMT) is a cytosolic S-adenosyl-L-methionine (SAM)-
dependent methyltransferase that catalyzes the methylation of nicotinamide (NAM) to form N-
methylnicotinamide (Me-NAM) and S-adenosyl-L-homocysteine (SAH) as a by-product (Figure 
1A).1, 2  NNMT also methylates numerous other pyridine-containing compounds.3 Although 
widely expressed, NNMT is predominantly found in the liver, where it detoxifies xenobiotics by 
producing N-methylated metabolites.1-9  Additionally, NNMT regulates NAD+ biosynthesis.8, 10 
Overexpression of NNMT is linked with several diseases, including Parkinson’s disease where it 
has been proposed to generate N-methylated pyridiniums that are dopaminergic toxins,11, 12 
although this idea is controversial.3, 13  NNMT also regulates adiposity by altering intracellular 
NAD+ and SAM levels.  Notably, higher NNMT levels are observed in the white adipose tissue 
of mice suffering from obesity and type 2 diabetes.14  Interestingly, NNMT knockdown increases 
energy expenditure and prevents weight gain in mice receiving a fat-enriched diet.  These data 
clearly indicate a relationship between NNMT and obesity.8  Finally, increased NNMT activity 
alters the intracellular levels of SAM, which interferes with the methylation of DNA and 
histones and thereby modulates gene expression.15  This effect ultimately impacts a variety of 
cancers of the lung,16 thyroid,17, 18 brain,19 kidney,20 bladder,19 pancreas, and stomach.21  Notably, 
NNMT knockdown decreases cell migration, proliferation, and metastasis. 
Given the therapeutic potential of NNMT, there is increasing interest in developing 
NNMT inhibitors.  NNMT is a small 29 kDa globular protein that is structurally related to other 
Class-I SAM-dependent methyltransferases.22  Structures of NNMT bound to NAM and SAH 
have been determined and are consistent with the direct transfer of a methyl group to the pyridine 
nitrogen.22  Recently, we showed that human NNMT uses a rapid equilibrium ordered 
mechanism where SAM binds first followed by NAM.  Methyltransfer occurs at which point 
Me-NAM is released, followed by SAH.23  A limited number of NNMT inhibitors have been 
reported.  For example, the product inhibitors Me-NAM and SAH are reasonably potent (Ki 
(MeNAM) = 27 µM and Ki (SAH) = 3 µM, respectively) reversible inhibitors that we used to determine 
the kinetic mechanism of NNMT (see above). Several quinolines are also reversible inhibitors.24 
Recently, bisubstrate inhibitors (IC50 ~ 20 µM) were developed by conjugating NAM and SAM 
through an alkyl linker.25, 26  6-methoxynicotinamide, another reversible NNMT inhibitor (IC50 = 
1.8 µM) reduces Me-NAM levels and body weight gain in mouse models of metabolic 
diseases.27  Cravatt and colleagues also described the first irreversible NNMT inhibitor (kobs/[I] = 
21 M-1s-1).  This compound uses a cysteine-targeted α-chloroacetamide warhead and covalently 
modifies C165, a non-catalytic cysteine present in the active site.28  
Fast reported that 4-chloropyridines (Figure 1B) covalently modify the active-site 
cysteine in dimethylarginine dimethyliminohydrolase (DDAH), an unrelated enzyme.29-32  While 
the neutral form of 4-choloropyridine was unreactive, protonation of the pyridine ring nitrogen 
by the enzyme enhanced the electrophilicity of the 4-chloro position (Figure S1).  N-methylation 
mimicked this effect. Given the presence of cysteines in the active-site of NNMT, we questioned 
whether NNMT might accept halogenated pyridines as substrates to generate its own inhibitor 
(Figure 1C).  A major advantage of this “suicide inhibition” strategy is reduced off-target 
toxicity since NNMT is generating its own inhibitor. 
To test this hypothesis, we first determined whether N-methyl-4-chloropyridine (1, 
Figure 1B) inactivates NNMT.  Here, we incubated purified NNMT with 1 and monitored the 
residual methyltransferase activity at different times by monitoring SAH production (Figure 1D). 
Gratifyingly, compound 1 exhibited time and concentration-dependent inhibition consistent with 
an irreversible inactivation mechanism.  From the time-dependence data, we calculated a kinact/KI 
value of 44±3 M-1min-1 (Figure 1E), which is similar to that obtained for the inactivation of 
DDAH by 4-halopyridines.  Next, we incubated 1 with NNMT and measured the intact mass of 
the protein.  The 90 Da mass increase is consistent with the expected mass change of 92 Da for a 
singly modified protein (Figure S2).  We confirmed irreversibility by measuring activity after 
dialysis; there was no recovery of activity consistent with the covalent inactivation of NNMT by 
1 (Figure S3). 
Having confirmed that N-methyl-4-chloropyridine irreversibly inhibits NNMT, we next 
determined whether 4-chloropyridine (2) is an NNMT substrate (Figure 1C) by measuring SAH 
production.  Gratifyingly, the initial rate data exhibit Michaelis-Menten kinetics (Table S1) and 
the KM of 2 (KM(2) = 44 µM) is similar to that obtained for NAM (KM (NAM) = 7 µM).  Next, we 
tested a small library of chloropyridines (compounds 3-5, Figure 1B).  Like 2, NNMT methylates 
compound 3 (KM(3) = 23 µM) indicating that the 4-chloro substitution is well tolerated.  By 
contrast, compounds 4 and 5 were not methylated suggesting that substitution of the 2-position is 
forbidden (Figure 2A). 
We next investigated whether N-methylation facilitates enzyme inactivation by 
incubating 2 and 3 with NNMT and SAM for 0.5 h.  Unreacted small molecules were removed 
with a desalting column and residual activity assayed by measuring quinoline methylation; 1-
methyl-quinoline is fluorescent.33 Quinoline is a known NNMT substrate (KM(Q) = ~17 µM and 
kcat = ~ 0.75 min
-1), which we used to determine the kinetic mechanism of NNMT.23 This 
fluorescence assay minimizes the interference from residual SAH that was not removed by the 
desalting column.  Using this assay, we found that 2 and 3 inactivate NNMT similarly to 
compound 1 (Figure 2B).  Moreover, both compounds exhibit time-dependent enzyme 
inactivation kinetics with kobs/[I] values of 20±1 M
-1min-1 for 2 and 80±2.5 M-1min-1 for 3 
(Figure 2C).  The covalent modification of NNMT by 2 and 3 was confirmed by mass 
spectrometry.  The observed mass shifts (90 and 134 Da) are consistent with those expected for 
NNMT modified by a single molecule of 2 (92 Da) or 3 (135 Da).  Note, we did observe a small 
amount of NNMT modified by two molecules of 3 (Figure 2D-F, Table S2).  Taken together, 
these data demonstrate that 2 and 3 are suicide inhibitors that rely on NNMT catalysis to 
generate the reactive species.    
 
Since N-methyl-chloropyridines preferentially target cysteine, we next identified the 
cysteine that is modified.  Based on the NNMT-NAM-SAH crystal structure (PDB ID: 3ROD), 
we identified two non-catalytic cysteines out of total 8 cysteine residues, C159 and C165, that 
were closer to the active site than the others (Figure 3A).  Notably, Cravatt and colleagues 
showed that covalent modification of C165 inhibits NNMT activity.28  Given these data, we 
generated the C159A, C165A and C159/165A mutants to confirm whether enzyme inactivation 
is due to the covalent modification of one or both residues.  The three mutants were purified and 
the steady state kinetic parameters were determined (Table S1).  Although the kcat of the 
C159/165A double mutant is reduced by ~10 fold, neither single mutant showed any effect on 
this parameter.  Moreover, there were minimal effects on KM.  These results suggest that C159 
and C165 are not important for substrate binding but instead act as second shell residues that 
indirectly influence catalysis.   
Next, we showed that these mutants methylate 2 and 3 (Figures 3B, S4 and Table S1). 
Compared to wild-type NNMT, kcat is ~10-fold lower.  The reason for the decreased rate of 
methylation of 2 and 3 is not immediately clear.  Interestingly, the IC50 values of 1 for wild-type 
NNMT and the C165A mutant are similar.  By contrast, little to no inhibition was observed for 
the C159A and C159/165A mutants (Figure 3C).  Similarly, when we evaluated the ability of 2 
and 3 to act as suicide inhibitors, we saw no inhibition of the C159A mutant (Figure 3D).  By 
contrast, the C165A mutant remained sensitive.  Unfortunately, we could not evaluate 
C159/165A NNMT mutant in this assay set-up as this mutant was inactive after passing through 
the desalting column.  Nevertheless, these results unambiguously indicate that C159 is covalently 
modified by N-methyl-4-chloropyridine and N-methyl-4-chloronicotinamide.  These 
observations are also consistent with the mass shifts obtained from MS studies (Figure S5, Table 
S3).  The NNMT-NAM-SAH structure adopts a highly compact fold and C159 is not directly 
accessible from the active site.  This data indicates that the during the catalytic cycle the enzyme 
must undergo a conformational change to either increase its accessibility and/or release the 
activated inhibitor such that it can rebind to NNMT adjacent to C159.    
Building on these findings, we next developed a suicide inhibition-based protein labeling 
(SIBLing) strategy using compound 6 (Figure 1); 6 contains an alkyne that can be conjugated 
with a reporter tag via the copper-catalyzed azide-alkyne cycloaddition (CuAAC) reaction after 
enzyme inactivation.  Gratifyingly, compound 6 is methylated by NNMT and the kinetic values 
are similar to those obtained for 2, 3, and NAM (Table S1), thereby indicating that the alkyne 
does not impact the binding affinity of 6 (Figure 4A).  Having established that 6 is also an 
NNMT substrate, we next treated NNMT with 6 and SAM.  Notably, this treatment readily 
inactivated the enzyme (Figure 4B).  The intact mass of the modified protein is consistent with 
the addition of a single molecule of 6 (Figure 4B, inset).  Next, we determined whether 6, as well 
as 2 and 3, can inhibit cellular NNMT activity. For these studies, NNMT overexpressing 
HEK293T cells were treated with increasing concentrations of 2, 3 and 6 for 2 h.  Cells were 
lysed and NNMT activity was measured.  The results showed that 2, 3 and 6 inhibit cellular 
NNMT activity with EC50 values in the double digit micro molar range respectively (Figure S6). 
 Having established that 6 is a suicide inhibitor and can inhibit cellular NNMT activity, 
we next treated NNMT with a mixture of SAM and 6 and then used CuAAC to couple the alkyne 
to TAMRA-N3.  Gratifyingly, compound 6 dose-dependently labeled NNMT (Figure 4C). 
Notably, the limit of detection is 7 pmol of NNMT (Figure 4D).  These results demonstrate that 
NNMT methylates 6 to generate its own probe.  To the best of our knowledge, this compound is 
the first small-molecule probe that relies on suicide-inhibition.  Since 6 inhibits cellular NNMT 
activity, we next treated HEK293T-NNMT cells as well as cell lysates with increasing 
concentrations of 6 in the presence of SAM.  The labeled proteins were then “clicked” to 
TAMRA-N3.  Notably, we observed a dose-dependent increase in the labeling of NNMT by 
compound 6 (Figure 4E, S7). Similar results were obtained for SKOV-3 cells, which 
endogenously express NNMT (Figure 4F, S7).  In addition to NNMT, 6 labels a small number of 
other proteins in both cell lines.  This result can easily be explained if N-methylation is faster 
than enzyme inactivation and the N-methylated product can diffuse out of the active site and 
react with other proteins leading to off-target labeling.  To confirm this possibility, we measured 
the partition ratio, i.e. the molar ratio of inactivator to enzyme required to completely abolish 
enzymatic activity.  For compound 6, this ratio is ~ 200 (Figure S8), consistent with the notion 
that the suicide inhibitor diffuses out of the active site and rebinds to react with C159. 
In conclusion, we developed a novel suicide-inhibition strategy for NNMT, which is 
overexpressed in several types of cancers and many chronic diseases.  This strategy utilizes 4-
chloropyridine (2) and 4-chloronicotinamide (3) as NNMT substrates to generate the 
corresponding N-methylated products.  In turn, these compounds inhibit NNMT by covalently 
modifying C159 which lies adjacent to the active site. Since these compounds rely on enzyme 
catalysis to generate the reactive species, they are mechanism-based inactivators.  However, if 
inactivation requires release and rebinding, they could also be deemed pro-drugs.29 Experiments 
to distinguish these possibilities are ongoing.  Building on this discovery, we also developed a 
suicide inhibition-based protein labeling (SIBLing) strategy using compound 6, which efficiently 
labels recombinant as well as cellular NNMT. Despite their modest potency, these compounds 
serve as a foundation for developing more efficient NNMT inhibitors. Future efforts are focused 
on incorporating the 4-chloropyridine warhead into larger inhibitor scaffolds to develop suicide 
inhibitors with improved potency and selectivity.     
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Figure Legends 
Figure 1. (A) NNMT reaction. (B) Compounds 1-6. (C) Inactivation of NNMT by 3. (D) 
Inactivation of NNMT by 1. (E)  Plot of (kobs) versus [I] for 1. All experiments were performed 
in duplicate (n = 2). 
 
Figure 2. (A) Compounds 2 and 3 are NNMT substrates. (B) Inactivation of NNMT by 2 and 3 
plus SAM. Compounds (0.5 mM) were incubated with NNMT for 0.5 h and residual activity 
assayed. (C) Inactivation of NNMT by 2 and 3 plus SAM.  Note that the errors were so small 
that the error bars lie within the data points. (D, E, F) The deconvoluted molecular weights for 
unmodified NNMT and NNMT containing an uncleaved N-formyl-methionine (NNMTa), 2-
modified NNMT, and 3-modified NNMT.  All experiments were performed in duplicate (n = 2). 
 
Figure 3. (A) Active site of NNMT highlighting C159 and C165. (B) NNMT and the C159A, 
C165A and C159/165A mutants methylate 3. (C) Compound 1 inhibits NNMT and the C165A 
mutant but not the C159A or C159/165A mutants. (D) Inactivation of NNMT, C159A and 
C165A by 2 and 3 plus SAM.  All experiments were performed in duplicate (n = 2). 
 
Figure 4. (A) Compound 6 is an NNMT substrate.  Note that the errors are so small that the error 
bars lie within the data points.  (B) Inactivation of NNMT by 6 plus SAM.  Deconvoluted mass 
of NNMT-6 complex (inset).  (C) Concentration-dependent labeling of recombinant NNMT with 
6. F and C stand for fluorograph and Coomassie stain.  (D) Limit of detection study. (E) 
Concentration-dependent labeling of HEK293T cell lysates (spiked with 0.5 µg of recombinant 
NNMT) by 6. R stands for recombinant NNMT. (F) Concentration dependent labeling of 
SKOV3 cell lysates with 6.  All experiments were performed in triplicate (n = 3). 
 
